Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Ondine Biomedical Inc. announced the issuance of 800,457 common shares to the Royal Columbian Hospital Foundation following the completion of patient enrollment in a groundbreaking ICU nasal photodisinfection trial using Steriwave. This share issuance marks a significant milestone in the trial, which aims to explore the feasibility of Steriwave as a nasal decolonization tool in intensive care settings, potentially impacting the company’s market position in the ICU infection prevention sector.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for infection prevention and treatment. The company has a range of investigational products based on its proprietary technology, with approvals in several countries and ongoing trials for regulatory approval in the US.
Average Trading Volume: 166,062
Technical Sentiment Signal: Buy
Current Market Cap: £57.62M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.